Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar

The document described two cases of Hidradenitis Suppurativa (HS) treated with adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar. The first patient, a 59-year-old male with a long history of HS, diabetes mellitus type II, and hypertension, showed significant improvement after 16 weeks of adalimumab treatment, with a decrease in the Dermatology Life Quality Index (DLQI) from 24 to 3. The second patient, a 28-year-old male, also experienced a reduction in DLQI from 14 to 3 after 16 weeks of adalimumab therapy. Both patients had previously been treated with antibiotics and other therapies without sufficient response. The study highlighted the effectiveness of adalimumab, the only biologic agent approved by the FDA and EMA for moderate-to-severe HS, in reducing the severity of lesions and improving the quality of life in patients unresponsive to conventional treatments.